These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. Barash U; Cohen-Kaplan V; Dowek I; Sanderson RD; Ilan N; Vlodavsky I FEBS J; 2010 Oct; 277(19):3890-903. PubMed ID: 20840586 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912 [TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902 [TBL] [Abstract][Full Text] [Related]
6. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin. Elli S; Guerrini M Adv Exp Med Biol; 2020; 1221():169-188. PubMed ID: 32274710 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of heparanase inhibitors in cancer therapy. Heyman B; Yang Y Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132 [TBL] [Abstract][Full Text] [Related]
8. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720 [TBL] [Abstract][Full Text] [Related]
9. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway. Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511 [TBL] [Abstract][Full Text] [Related]
10. Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity. Zhang Y; Wang N; Raab RW; McKown RL; Irwin JA; Kwon I; van Kuppevelt TH; Laurie GW J Biol Chem; 2013 Apr; 288(17):12090-101. PubMed ID: 23504321 [TBL] [Abstract][Full Text] [Related]
11. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. Sasaki N; Higashi N; Taka T; Nakajima M; Irimura T J Immunol; 2004 Mar; 172(6):3830-5. PubMed ID: 15004189 [TBL] [Abstract][Full Text] [Related]
12. Heparanase involvement in physiology and disease. Nasser NJ Cell Mol Life Sci; 2008 Jun; 65(11):1706-15. PubMed ID: 18425416 [TBL] [Abstract][Full Text] [Related]
13. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281 [TBL] [Abstract][Full Text] [Related]
14. Heparanase regulates levels of syndecan-1 in the nucleus. Chen L; Sanderson RD PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494 [TBL] [Abstract][Full Text] [Related]
15. Tumorigenic and adhesive properties of heparanase. Levy-Adam F; Ilan N; Vlodavsky I Semin Cancer Biol; 2010 Jun; 20(3):153-60. PubMed ID: 20619346 [TBL] [Abstract][Full Text] [Related]
16. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925 [TBL] [Abstract][Full Text] [Related]